News >

Subcutaneous Daratumumab Succeeds in Phase III Myeloma Trial

OncLive Staff
Published: Monday, Feb 25, 2019

Jan van de Winkel, PhD

Jan van de Winkel, PhD
A subcutaneous (SC) formulation of daratumumab is noninferior in inefficacy and pharmacokinetics compared with standard intravenous (IV) daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma, according to data from the phase III COLUMBA study.1

Additionally, the safety profiles were similar across both dosing regimens.

References

  1. Genmab Announces Positive Topline Results in Phase III COLUMBA Study of Subcutaneous Daratumumab. Published February 25, 2019. Accessed February 25, 2019. https://bit.ly/2tCig7V.
  2. Chari AJ, Martinez-Lopez J, Mateos MV, et al. Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001. J Clin Oncol. 2018;36 (suppl; abstr 8002).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x